Objective: The objective of this study was to assess the validity of women's reports of recent unprotected sex by testing for prostate-specific antigen (PSA) [a protein produced by the prostate gland and secreted into the urethra during ejaculation can be detected in vaginal fluid samples with high sensitivity] in vaginal samples.
New methods are now available, and others are being developed, that could enable women to take the initiative in preventing sexually transmitted infections. However, attempts to capitalize on ''female-controlled'' preventive methods thus far have met with limited success. Female-initiated methods were introduced to intervene in the state of gender relations and assist women who are disempowered vis-à-vis their male partners. Paradoxically, however, we underscore that it is the very structure of regional and local gender relations that shapes the acceptability (or lack of acceptability) of these methods. This paper specifically addresses how the structure of gender relations-for better and for worse-shapes the promises and limitations of widespread use and acceptance of female-initiated methods. We draw on examples from around the world to underscore how the regional specificities of gender (in)equality shape the acceptance, negotiation, and use of these methods. Simultaneously, we demonstrate how the introduction and sustained use of methods are shaped by gender relations and offer possibilities for reinforcing or challenging their current state. Based on our analyses, we offer key policy and programmatic recommendations to increase promotion and effective use of women-initiated HIV/STI protection methods for both women and men. In the MIRA study, the most common sizes of diaphragms distributed to participants were: 70mm (36%), 75mm (19%), 65mm (18%) and 80mm (10%). Diaphragm sizing was monitored through peer review by clinicians, bi-annual external monitoring and review of size distribution curves. Monitoring resulted in the identification of discrepancies in real time which led to corrective measures being implemented during the trial including clinician retraining. Regular monitoring to ensure standardized fitting procedures has been an important component of the successful implementation of the MIRA trial.
Clouse K. et al. Partner awareness and support of diaphragm and microbicidal gel use
Researchers asked 119 married Zimbabwean women aged 18-49 in a safety trial of the diaphragm and microbicide candidate Cellulose Sulfate (CS) to describe their experiences using their products, their partners' reactions and the importance of being able to use a method discreetly. While most participants (94%) reported that their partners were supportive or neutral to product use, 35% said that product use without their partner's knowledge was important to them. Half of the women also believed that the study products could be used discreetly outside of a study situation. Partner awareness and/or support did not differ whether the gel was used alone or when the diaphragm and gel were used together.
Terris-Prestholt F. et al. Distributing barrier methods for women: determinants of willingnessto-pay for microbicides, the diaphragm and female condom
This study explored key determinants of women's willingness-to-pay for microbicides, the diaphragm and female condom. Researchers asked 1,017 women in a township in Johannesburg, South Africa if they would be willing to try each product, if they thought they would use it regularly and what they would be willing to pay to purchase each product. Women were most willing to try microbicides (74%), followed by the diaphragm (60%) and the female condom (56%). If available, 78-95% of women reported that they would/ could use the products regularly.
Researchers concluded that with careful price setting, it would be possible to recover some costs from women of higher socio-economic status while subsidized distribution would be necessary to reach lowerincome women.
Montandon M. et al. Adolescent girls' perspectives on research on femalecontrolled HIV prevention methods in Kenya
Few microbicide and cervical barrier effectiveness trials include female participants under 18, despite the high risk of HIV infection among this population.
To understand the views of adolescents and their communities, researchers conducted 30 semi-structured interviews and 3 focus group discussions with adolescent girls aged 14-17 in Kisimu, Kenya. Results showed that while condoms and abstinence were cited as HIV prevention options, participants state that these methods did not work well for girls. Although there was a fear of girls being the first group to try an experimental product, participants also reported that they thought microbicides and the diaphragm would be easy for girls to use. Because adolescent girls may fear being the first to try a new product, safety and/or effectiveness data from adult women may be important to recruit girls into clinical trials. Carrageenan is a substance that is extracted from seaweed for use as a thickening agent in baby food, sexual lubricants and other consumer products. A new research study 1 has found that carrageenan is effective in vitro against a range of common types of the sexually transmitted human papilloma virus (HPV) known to cause cervical cancer and genital warts. Due to its safety record in food and topical applications, carrageenan is an exciting potential candidate as a microbicide for preventing HPV. However, clinical trials to determine the efficacy of carrageenan in humans against HPV are necessary to determine whether the efficacy in the lab translates to protection for humans. A formulation of carrageenan also is currently being tested in a major clinical trial in South Africa as a topical microbicide targeting HIV and herpes viruses. 
CBAS Updates Cervical Barrier Trial Information
Go to www.cervicalbarriers.org/information/ trialsAndResearch.cfm for up-to-date information on recently completed, current and planned research related to cervical barrier methods. Thanks to all of the researchers who contributed information about their studies to make this summary a valuable resource. Ramjee is also leading trials to develop ARV therapies and microbicides. In fact, HPRU is currently conducting clinical trials with 4 out of 5 microbicide products that have reached advanced stages of clinical development. Dr. Ramjee's passion has been to utilize scientific innovation in the field of HIV prevention to address gender imbalances and the threat of domestic violence which make safe sex practices impossible for some African women. To learn more about Dr. Ramjee's work at HPRU, go to their website and read their newly launched newsletter called, "iThemba" at www.mrc.ac.za/hiv/itembajuly2006.pdf. iThemba is the isiZulu word for "hope" which signifies HPRU's commitment toward finding effective HIV prevention options. The Population Association of America is a nonprofit, scientific, professional organization dedicated to research on problems related to human population. The Annual Meeting provides a forum for the presentation of scientific papers, workshops, discussion groups and job opportunities.
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What are cervical barriers?
Most people think of cervical barriers primarily as the diaphragm and cervical cap but a broader definition would encompass Lea's shield, female and male condoms, the sponge and microbicides. For more information about the range of cervical barrier methods, go to http://www.cervicalbarriers.org/information/methods.cfm.
Mission of CBAS
Established in 2004, the Cervical Barrier Advancement Society (CBAS) aims to raise the profile of cervical barrier methods for pregnancy prevention and provide information about research on the potential of cervical barriers to prevent sexually transmitted infections, including HIV.
Membership
CBAS membership is free and open to all who are interested in joining. CBAS's goal is to create an international, professional networking organization including clinical and social science research groups, academic institutions, advocacy groups, trade associations, and pharmaceutical, biotech, and medical device companies. As a member, you will have the opportunity to network and collaborate with other professionals in the field; keep abreast of new research; share information and ideas; and receive a semi-annual newsletter.
CBAS Contact Information:
For more information, contact Julia Matthews, CBAS Executive Director at jmatthews@cervicalbarriers.org. CBAS is hosted by Ibis Reproductive Health and based in Cambridge, Massachusetts.
